- Home
- FENG vs LPCN Comparison
FENG vs LPCN Comparison
Compare FENG & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FENG
- LPCN
- Stock Information
- Founded
- FENG 1998
- LPCN 1997
- Country
- FENG China
- LPCN United States
- Employees
- FENG N/A
- LPCN N/A
- Industry
- FENG Broadcasting
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- FENG Industrials
- LPCN Health Care
- Exchange
- FENG Nasdaq
- LPCN Nasdaq
- Market Cap
- FENG 29.7M
- LPCN 27.1M
- IPO Year
- FENG 2011
- LPCN N/A
- Fundamental
- Price
- FENG $2.49
- LPCN $4.37
- Analyst Decision
- FENG
- LPCN Strong Buy
- Analyst Count
- FENG 0
- LPCN 1
- Target Price
- FENG N/A
- LPCN $10.00
- AVG Volume (30 Days)
- FENG 3.6K
- LPCN 34.0K
- Earning Date
- FENG 03-11-2025
- LPCN 03-06-2025
- Dividend Yield
- FENG N/A
- LPCN N/A
- EPS Growth
- FENG N/A
- LPCN N/A
- EPS
- FENG N/A
- LPCN N/A
- Revenue
- FENG $99,426,474.00
- LPCN $7,922,926.00
- Revenue This Year
- FENG N/A
- LPCN N/A
- Revenue Next Year
- FENG N/A
- LPCN N/A
- P/E Ratio
- FENG N/A
- LPCN N/A
- Revenue Growth
- FENG N/A
- LPCN N/A
- 52 Week Low
- FENG $1.20
- LPCN $3.20
- 52 Week High
- FENG $4.15
- LPCN $11.79
- Technical
- Relative Strength Index (RSI)
- FENG 51.73
- LPCN 38.51
- Support Level
- FENG $2.31
- LPCN $4.48
- Resistance Level
- FENG $2.65
- LPCN $4.89
- Average True Range (ATR)
- FENG 0.11
- LPCN 0.35
- MACD
- FENG 0.01
- LPCN -0.06
- Stochastic Oscillator
- FENG 54.29
- LPCN 9.60
About FENG Phoenix New Media Limited
Phoenix New Media Ltd is a media company providing premium content on an integrated platform across the internet, mobile and TV channels in China. The company organizes its operations into two main segments: Net advertising services and Paid services. It provides its content and services through three channels: ifeng.com channel, video channel, and mobile channel. The company also offers a wide range of paid services including mobile value-added services, games, and content sales. It generates the majority of its revenue from Net advertising services. Geographically, it derives revenue from China.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.